Reithinger R, Dujardin JC, Louzir H, Pirmez C, Alexander B, Brooker S, 2007. Cutaneous leishmaniasis. Lancet Infect Dis 7: 581–596.
Gonzalez U, Pinart M, Reveiz L, Alvar J, 2008. Interventions for Old World cutaneous leishmaniasis. Cochrane Database Syst Rev CD005067.
Blum J, Desjeux P, Schwartz E, Beck B, Hatz C, 2004. Treatment of cutaneous leishmaniasis among travellers. J Antimicrob Chemother 53: 158–166.
Mondal S, Bhattacharya P, Ali N, 2010. Current diagnosis and treatment of visceral leishmaniasis. Expert Rev Anti Infect Ther 8: 919–944.
Calvopina M, Gomez EA, Sindermann H, Cooper PJ, Hashiguchi Y, 2006. Relapse of new world diffuse cutaneous leishmaniasis caused by Leishmania (Leishmania) mexicana after miltefosine treatment. Am J Trop Med Hyg 75: 1074–1077.
Mohebali M, Fotouhi A, Hooshmand B, Zarei Z, Akhoundi B, Rahnema A, Razaghian AR, Kabir MJ, Nadim A, 2007. Comparison of miltefosine and meglumine antimoniate for the treatment of zoonotic cutaneous leishmaniasis (ZCL) by a randomized clinical trial in Iran. Acta Trop 103: 33–40.
Soto J, Toledo JT, 2007. Oral miltefosine to treat new world cutaneous leishmaniasis. Lancet Infect Dis 7: 7.
Tappe D, Muller A, Stich A, 2010. Resolution of cutaneous old world and new world leishmaniasis after oral miltefosine treatment. Am J Trop Med Hyg 82: 1–3.
Faber WR, Wonders J, Jensema AJ, Chocholova E, Kager PA, 2009. Cutaneous leishmaniasis with lymphadenopathy due to Leishmania donovani. Clin Exp Dermatol 34: e196–e198.
Neub A, Krahl D, Stich A, Amon U, 2008. Cutaneous infection with Leishmania infantum in an infant treated successfully with miltefosine. J Dtsch Dermatol Ges 6: 1061–1064.
van Eys GJ, Schoone GJ, Kroon NC, Ebeling SB, 1992. Sequence analysis of small subunit ribosomal RNA genes and its use for detection and identification of Leishmania parasites. Mol Biochem Parasitol 51: 133–142.
Dujardin JC, Campino L, Canavate C, Dedet JP, Gradoni L, Soteriadou K, Mazeris A, Ozbel Y, Boelaert M, 2008. Spread of vector-borne diseases and neglect of leishmaniasis, Europe. Emerg Infect Dis 14: 1013–1018.
Haralambous C, Antoniou M, Pratlong F, Dedet JP, Soteriadou K, 2008. Development of a molecular assay specific for the Leishmania donovani complex that discriminates L. donovani/Leishmania infantum zymodemes: a useful tool for typing MON-1. Diagn Microbiol Infect Dis 60: 33–42.
Nicholas KB, Nicholas HB Jr., Deerfield DW II, 1997. GeneDoc: analysis and visualization of genetic variation. Embnet News 4: 1–4.
Antinori S, Gianelli E, Calattini S, Longhi E, Gramiccia M, Corbellino M, 2005. Cutaneous leishmaniasis: an increasing threat for travellers. Clin Microbiol Infect 11: 343–346.
Alam MZ, Haralambous C, Kuhls K, Gouzelou E, Sgouras D, Soteriadou K, Schnur L, Pratlong F, Schonian G, 2009. The paraphyletic composition of Leishmania donovani zymodeme MON-37 revealed by multilocus microsatellite typing. Microbes Infect 11: 707–715.
Mazeris A, Soteriadou K, Dedet JP, Haralambous C, Tsatsaris A, Moschandreas J, Messaritakis I, Christodoulou V, Papadopoulos B, Ivovic V, Pratlong F, Loucaides F, Antoniou M, 2010. Leishmaniases and the Cyprus paradox. Am J Trop Med Hyg 82: 441–448.
Antoniou M, Haralambous C, Mazeris A, Pratlong F, Dedet JP, Soteriadou K, 2008. Leishmania donovani leishmaniasis in Cyprus. Lancet Infect Dis 8: 6–7.
Past two years | Past Year | Past 30 Days | |
---|---|---|---|
Abstract Views | 593 | 548 | 216 |
Full Text Views | 364 | 11 | 2 |
PDF Downloads | 81 | 14 | 2 |
A patient presenting with an atypical manifestation of cutaneous leishmaniasis after travel to Cyprus was successfully treated with miltefosine. The K26 typing revealed a hitherto undescribed strain of the Leishmania donovani/infantum complex as the causing agent.
Authors' addresses: Wolfgang Poeppl, Tom Pustelnik, and Gerhard Mooseder, Department of Dermatology, Military Hospital Vienna, Vienna, Austria, E-mails: wolfgang.poeppl@meduniwien.ac.at, tom@hautarztpustelnik.at, and gmoos@gmx.at. Julia Walochnik and Herbert Auer, Institute of Specific Prophylaxis and Tropical Medicine, Department of Medical Parasitology, Medical University of Vienna, Vienna, Austria, E-mails: julia.walochnik@meduniwien.ac.at and herbert.auer@meduniwien.ac.at.
Reithinger R, Dujardin JC, Louzir H, Pirmez C, Alexander B, Brooker S, 2007. Cutaneous leishmaniasis. Lancet Infect Dis 7: 581–596.
Gonzalez U, Pinart M, Reveiz L, Alvar J, 2008. Interventions for Old World cutaneous leishmaniasis. Cochrane Database Syst Rev CD005067.
Blum J, Desjeux P, Schwartz E, Beck B, Hatz C, 2004. Treatment of cutaneous leishmaniasis among travellers. J Antimicrob Chemother 53: 158–166.
Mondal S, Bhattacharya P, Ali N, 2010. Current diagnosis and treatment of visceral leishmaniasis. Expert Rev Anti Infect Ther 8: 919–944.
Calvopina M, Gomez EA, Sindermann H, Cooper PJ, Hashiguchi Y, 2006. Relapse of new world diffuse cutaneous leishmaniasis caused by Leishmania (Leishmania) mexicana after miltefosine treatment. Am J Trop Med Hyg 75: 1074–1077.
Mohebali M, Fotouhi A, Hooshmand B, Zarei Z, Akhoundi B, Rahnema A, Razaghian AR, Kabir MJ, Nadim A, 2007. Comparison of miltefosine and meglumine antimoniate for the treatment of zoonotic cutaneous leishmaniasis (ZCL) by a randomized clinical trial in Iran. Acta Trop 103: 33–40.
Soto J, Toledo JT, 2007. Oral miltefosine to treat new world cutaneous leishmaniasis. Lancet Infect Dis 7: 7.
Tappe D, Muller A, Stich A, 2010. Resolution of cutaneous old world and new world leishmaniasis after oral miltefosine treatment. Am J Trop Med Hyg 82: 1–3.
Faber WR, Wonders J, Jensema AJ, Chocholova E, Kager PA, 2009. Cutaneous leishmaniasis with lymphadenopathy due to Leishmania donovani. Clin Exp Dermatol 34: e196–e198.
Neub A, Krahl D, Stich A, Amon U, 2008. Cutaneous infection with Leishmania infantum in an infant treated successfully with miltefosine. J Dtsch Dermatol Ges 6: 1061–1064.
van Eys GJ, Schoone GJ, Kroon NC, Ebeling SB, 1992. Sequence analysis of small subunit ribosomal RNA genes and its use for detection and identification of Leishmania parasites. Mol Biochem Parasitol 51: 133–142.
Dujardin JC, Campino L, Canavate C, Dedet JP, Gradoni L, Soteriadou K, Mazeris A, Ozbel Y, Boelaert M, 2008. Spread of vector-borne diseases and neglect of leishmaniasis, Europe. Emerg Infect Dis 14: 1013–1018.
Haralambous C, Antoniou M, Pratlong F, Dedet JP, Soteriadou K, 2008. Development of a molecular assay specific for the Leishmania donovani complex that discriminates L. donovani/Leishmania infantum zymodemes: a useful tool for typing MON-1. Diagn Microbiol Infect Dis 60: 33–42.
Nicholas KB, Nicholas HB Jr., Deerfield DW II, 1997. GeneDoc: analysis and visualization of genetic variation. Embnet News 4: 1–4.
Antinori S, Gianelli E, Calattini S, Longhi E, Gramiccia M, Corbellino M, 2005. Cutaneous leishmaniasis: an increasing threat for travellers. Clin Microbiol Infect 11: 343–346.
Alam MZ, Haralambous C, Kuhls K, Gouzelou E, Sgouras D, Soteriadou K, Schnur L, Pratlong F, Schonian G, 2009. The paraphyletic composition of Leishmania donovani zymodeme MON-37 revealed by multilocus microsatellite typing. Microbes Infect 11: 707–715.
Mazeris A, Soteriadou K, Dedet JP, Haralambous C, Tsatsaris A, Moschandreas J, Messaritakis I, Christodoulou V, Papadopoulos B, Ivovic V, Pratlong F, Loucaides F, Antoniou M, 2010. Leishmaniases and the Cyprus paradox. Am J Trop Med Hyg 82: 441–448.
Antoniou M, Haralambous C, Mazeris A, Pratlong F, Dedet JP, Soteriadou K, 2008. Leishmania donovani leishmaniasis in Cyprus. Lancet Infect Dis 8: 6–7.
Past two years | Past Year | Past 30 Days | |
---|---|---|---|
Abstract Views | 593 | 548 | 216 |
Full Text Views | 364 | 11 | 2 |
PDF Downloads | 81 | 14 | 2 |